Epilepsy–Dementia–Amelogenesis Imperfecta Syndrome

Epilepsy–dementia–amelogenesis imperfecta syndrome is a genetic disease that a child gets when they inherit a faulty copy of a gene from both parents. The most common gene is ROGDI. The problem affects the brain and the teeth. In the brain, the condition makes seizures start early and can slowly reduce skills (like speaking, moving, and learning), which may look like dementia in a child. In the teeth, the enamel (the hard, shiny outer layer) is too thin, soft, and weak, so teeth look yellow–brown and wear down easily. There is no single cure yet. Care focuses on controlling seizures, protecting development, and restoring teeth so the child can eat, speak, and smile comfortably. Genetic testing confirms the diagnosis and helps with family planning. PMC+1

This rare, inherited condition causes a triad of problems that often begin in the first months or years of life: (1) epilepsy (repeated seizures), (2) developmental regression/intellectual decline that can resemble dementia in children, and (3) amelogenesis imperfecta (weak, thin, discolored tooth enamel). The most established genetic cause is having two disease-causing variants in the ROGDI gene (autosomal recessive). Many reports and reviews describe the same core picture: infant-onset seizures that are hard to control, progressive developmental difficulties, and enamel defects producing yellow–brown teeth. PMC+2PMC+2

Epilepsy–dementia–amelogenesis imperfecta syndrome is a very rare inherited condition. It affects the brain and the teeth. Children usually develop seizures (epilepsy) early in life. After the seizures begin, many children lose skills they had already learned (this is called developmental regression), and over time they may have problems with memory, learning, and daily activities (this can look like childhood-onset dementia). Their teeth have a visible enamel problem called amelogenesis imperfecta. The enamel is thin, soft, or poorly mineralized. Teeth often look yellow-brown and break or wear down easily. This syndrome is most often caused by changes (mutations) in a gene called ROGDI and is inherited in an autosomal recessive pattern (a child inherits one changed copy of the gene from each parent). A similar, “look-alike” condition can also be caused by mutations in SLC13A5, a gene for a sodium-citrate transporter important for brain energy use and enamel mineralization. National Organization for Rare Disorders+3PubMed+3PubMed+3

Other names

Doctors and researchers use several names for the same or closely related conditions:

• Kohlschütter–Tönz syndrome (KTS) – the most widely used name in medical literature. PubMed

• Epilepsy–dementia–amelogenesis imperfecta syndrome – a descriptive name highlighting the core triad. Wikipedia

• Amelocerebrohypohidrotic syndrome – another synonym sometimes used in rare-disease catalogs. Orpha+1

• ROGDI-related disorder – used when a genetic test confirms ROGDI mutations. PubMed

• SLC13A5 citrate transporter disorder / DEE25 with amelogenesis imperfecta – a separate genetic condition with very similar features (neonatal epilepsy and enamel defects). National Organization for Rare Disorders+2PMC+2

Key facts

• The classic triad is epilepsy, psychomotor regression/intellectual disability, and amelogenesis imperfecta. Symptoms usually start in infancy or early childhood. PubMed

• KTS is autosomal recessive. It has been reported in very small numbers of families around the world. PubMed+1

• ROGDI is highly active in the brain; its exact function is still being studied. Animal and cell studies suggest roles in neuronal development and synaptic signaling. PMC+2Nature+2

• SLC13A5 encodes the sodium-citrate transporter (NaCT). Citrate is important for brain energy pathways and enamel mineralization; loss of transporter function causes neonatal seizures and enamel hypoplasia. National Organization for Rare Disorders+2PubMed+2

---

Types

There is no single official “type” list, but in practice clinicians think about three helpful groupings:

1. Classic, ROGDI-related KTS (infant/early-childhood onset): seizures begin in the first years of life, followed by developmental regression and lifelong enamel defects affecting baby and adult teeth. PubMed+1

2. KTS-like, SLC13A5-related disorder (neonatal onset): seizures start in the first hours to days after birth; enamel is hypoplastic/hypomineralized due to impaired citrate transport. Cognitive and motor difficulties are common. Frontiers+1

3. Dental phenotype subtypes within KTS: patients may show hypoplastic enamel (too little enamel) or hypocalcified enamel (soft, chalky enamel). Both patterns have been reported with the neurologic features. Wikipedia

---

Causes

In this section, “cause” means either the root genetic reason or a biological mechanism that explains why features appear. Some items are core causes; others are well-supported mechanisms or recognized modifiers.

1. Biallelic ROGDI mutations: the main proven cause of classic KTS; inheritance is autosomal recessive. PubMed

2. Biallelic SLC13A5 mutations (NaCT deficiency): a separate disease that closely mimics KTS with seizures and enamel defects. National Organization for Rare Disorders+1

3. Autosomal-recessive inheritance with parental carrier status: when both parents carry one ROGDI variant, each child has a 25% chance to be affected. Consanguinity increases the chance that both parents carry the same rare variant. PubMed

4. Disrupted neuronal development and synaptic signaling from ROGDI loss: ROGDI is highly expressed in brain tissue; loss likely impairs normal neuron communication. PMC

5. Abnormal GABAergic signaling (experimental evidence): studies in model organisms suggest ROGDI influences GABA-mediated circuits that help regulate sleep and excitability; disturbance can favor seizures. Society for Developmental Biology

6. Energy-metabolism stress in the brain (SLC13A5): citrate import is blocked; this can disturb the TCA cycle and neuronal energy balance, lowering the seizure threshold. Frontiers

7. Defective enamel mineralization due to low enamel citrate (SLC13A5): citrate binds calcium in growing enamel; without NaCT, enamel is thin and weak. PubMed

8. Global ectodermal involvement: KTS is considered within the ectodermal dysplasia spectrum; enamel is ectoderm-derived, so genetic changes can affect teeth and sometimes hair/sweat. Wikipedia

9. Early-life seizures triggering regression: frequent uncontrolled seizures can lead to skill loss and worsening cognition over time. (Clinical neurology principle.)

10. Fever or intercurrent illness lowering seizure threshold: common seizure precipitants that can worsen epilepsy in affected children.

11. Sleep deprivation and stress: well-known seizure triggers that can magnify underlying genetic epilepsy.

12. Medication non-adherence: missing antiseizure doses can allow breakthrough seizures and regression.

13. Electrolyte imbalance (e.g., low sodium, low calcium): can provoke seizures on top of genetic vulnerability.

14. Hypoglycemia: low blood sugar may trigger seizures in a child already predisposed.

15. Head injury: traumatic brain injury can worsen seizures and cognitive function.

16. Coexisting infections of the central nervous system: meningitis/encephalitis can aggravate seizures and cognition.

17. Severe malnutrition: may impair brain development and enamel quality further.

18. Environmental neurotoxins (e.g., lead): can compound neurological impairment.

19. Untreated dental disease: pain and infection reduce nutrition and sleep, indirectly worsening seizures and development.

20. Diagnostic delay and late treatment: later control of seizures may allow more regression to occur.

---

Symptoms and signs

1. Seizures (epilepsy): usually start in infancy or early childhood. Types vary. Seizures may be frequent and hard to control at first. PubMed

2. Developmental delay or regression: a child may stop using words, lose motor or social skills, or plateau after seizures begin. PubMed

3. Childhood-onset dementia features: ongoing problems with memory, learning, and daily functioning that progress over time. PubMed

4. Amelogenesis imperfecta: thin, soft, or poorly formed enamel; teeth look yellow-brown, chip easily, and are sensitive to hot/cold. PubMed+1

5. Feeding and chewing problems: weak enamel and tooth pain make chewing hard foods difficult; nutrition can be affected.

6. Speech delay or loss of words: due to underlying brain involvement and regression. PubMed

7. Motor problems: low or high muscle tone, clumsiness, or stiffness; gross- and fine-motor skills may lag. PubMed

8. Behavioral challenges: irritability after seizures, attention problems, or autistic-like features in some children.

9. Sleep disturbance: seizures and neurological changes can disrupt sleep patterns.

10. Microcephaly in some cases: head size may be smaller than average in a subset of patients. Wikipedia

11. Coarse hair and other ectodermal signs (variable): hair/skin features can appear in some children. Wikipedia

12. Broad thumbs/toes or mild facial differences (variable): reported in some cases; not present in everyone. Wikipedia

13. Drooling and swallowing difficulty: oromotor dysfunction can occur with neurologic involvement.

14. Dental caries and early tooth wear: weak enamel leads to decay and rapid wear if not protected. Wikipedia

15. Heat intolerance or reduced sweating (occasionally reported): fits the ectodermal pattern suggested by the alternative name. Orpha

---

Diagnostic tests

Doctors use a stepwise approach. The goals are to (1) recognize the clinical triad, (2) rule out other causes, and (3) confirm the genetic diagnosis.

A) Physical examination

1. General pediatric and neurological exam: checks alertness, tone, reflexes, strength, coordination, gait, and signs of regression.

2. Developmental assessment: structured play and questions to measure speech, motor, social, and cognitive skills at the child’s age.

3. Detailed dental/oral exam: visualizes enamel thickness, color, surface quality, and chipping; looks for sensitivity and decay typical of amelogenesis imperfecta. Wikipedia

4. Growth and head-size charting: documents microcephaly or growth faltering if present. Wikipedia

5. Ectodermal survey: hair, nails, skin, and sweating pattern reviewed because KTS falls within an ectodermal dysplasia spectrum. Wikipedia

B) Manual/bedside tests

6. Neurologic bedside maneuvers: tone assessment, reflex testing, plantar response, and cerebellar tasks (finger-to-nose, tandem gait) to profile motor involvement.

7. Developmental screening tools (e.g., Denver-style items): quick checks of milestones to flag delays and regressions.

8. Oral pain/sensitivity probing: gentle percussion or air stimulus helps map enamel sensitivity and guide dental protection.

9. Seizure first-aid and trigger diary: families track events, sleep, fever, and medications; helps clinicians adjust treatment.

10. Family pedigree charting: documents autosomal-recessive patterns and consanguinity to support genetic suspicion. PubMed

C) Laboratory and pathological tests

11. Targeted or panel-based genetic testing for ROGDI: confirms the classic KTS diagnosis when a pathogenic variant is found on both gene copies. PubMed

12. Genetic testing for SLC13A5: pursued when seizures start neonatally or enamel is markedly hypoplastic; identifies citrate transporter deficiency. National Organization for Rare Disorders+1

13. Exome or genome sequencing: used when panel tests are negative, to discover or confirm rare variants in ROGDI, SLC13A5, or other enamel/brain genes. PubMed

14. Basic metabolic screen (glucose, electrolytes, calcium, magnesium): rules out treatable contributors to seizures.

15. Infection workup when indicated: to exclude CNS infection in acute presentations.

16. Dental material analysis (occasionally): specialized labs can examine enamel thin sections to document hypoplasia/hypomineralization; used mainly in research. Wikipedia

D) Electrodiagnostic tests

17. Electroencephalogram (EEG): records brain electrical activity to classify seizures and guide drug choice; video-EEG helps capture events safely.

18. Ambulatory/home EEG (when needed): extends recording time to catch intermittent seizures and assess sleep-related patterns.

E) Imaging tests

19. Brain MRI: looks for patterns of brain injury or atrophy that may accompany neurodegeneration/regression; also rules out other structural causes. Early literature describes the disorder as a CNS degenerative disease, which is compatible with nonspecific atrophy in some patients. PubMed

20. Dental radiographs (bitewing/panoramic): show thin enamel layers, irregular surfaces, accelerated wear, and secondary caries typical of amelogenesis imperfecta. Wikipedia

Non-pharmacological treatments (therapies & others)

Each item includes: what it is, purpose, mechanism—in simple words.

1. Seizure first-aid training for caregivers – keeps the child safe during a seizure; step-by-step actions reduce injury and emergency visits. Mechanism: preparedness and quick response. NCBI

2. Regular sleep plan – fixed sleep/wake times; reduces seizure triggers. Mechanism: stabilizes brain excitability. NCBI

3. Ketogenic diet (classic) under specialist team – high-fat, very low-carb diet to reduce seizures when medicines fail. Mechanism: switches brain fuel to ketones, which can dampen seizure networks. NICE+1

4. Modified Atkins/low glycemic index therapy – looser versions for some families; aim is similar seizure reduction. Mechanism: lower carbohydrate load → more ketones/stable glucose. NCBI

5. Vagus nerve stimulation (VNS) consideration – implanted device for drug-resistant seizures when resective surgery is not suitable. Mechanism: periodic vagus nerve signals modulate brain circuits to cut seizure frequency/severity. NICE

6. Physical therapy – stretching, balance, posture, spasticity management; preserves mobility and reduces falls. Mechanism: neural plasticity and muscle conditioning. NCBI

7. Occupational therapy – daily-living skills, feeding tools, hand function. Mechanism: task-specific practice builds independence. NCBI

8. Speech & language therapy (plus swallowing therapy) – communication and safe feeding; introduce AAC if needed. Mechanism: targeted repetition strengthens language/swallow patterns. NCBI

9. Neuropsychology & special education plans (IEP) – learning supports, behavior plans; reduces frustration and supports cognition. Mechanism: structured teaching and accommodations. NCBI

10. Behavioral therapy – addresses attention, anxiety, or behaviors that worsen learning; trains parents in strategies. Mechanism: reinforcement and routines. NCBI

11. Dental desensitizing care (varnish, desensitizers) – eases pain from exposed dentin. Mechanism: seals tubules, reduces nerve irritation. PMC

12. High-fluoride varnish and home fluoride – strengthens weak enamel and lowers cavities. Mechanism: fluoride promotes remineralization. AAPD

13. Protective stainless-steel crowns on baby molars – cover fragile enamel to stop wear and pain. Mechanism: full coverage shields tooth. PMC

14. Resin/composite restorations or veneers (permanent teeth) – restore shape/color; minimally invasive where possible. Mechanism: bonded materials replace lost enamel. PMC+1

15. Regular dental recalls (6–12 months) – early repairs and prevention as teeth erupt. Mechanism: proactive maintenance avoids crisis. BioMed Central

16. Mouthguards for bruxism – protect enamel if grinding is present. Mechanism: distributes forces and prevents chipping. PMC

17. Nutrition counseling – soft, non-acidic foods during sensitivity; adequate calories on seizure diets. Mechanism: reduces enamel acid attack and supports growth. BioMed Central

18. Care coordination (neurology–dentistry–rehab) – one plan across teams improves outcomes. Mechanism: reduces gaps and duplication. AAPD

19. Safety planning & SUDEP risk education – personalized seizure action plan, supervised bathing, monitor nocturnal seizures when advised. Mechanism: lowers injury and seizure-related risks. NCBI

20. Genetic counseling for family – explains inheritance, testing options for relatives, and future pregnancies. Mechanism: informed decisions and early detection. NCBI

---

Drug treatments

Important: Doses must be individualized by a specialist. Below are typical ranges seen in guidelines/standard references to give context—not personal medical advice.

1. Levetiracetam (broad-spectrum ASM).
   Class: SV2A modulator. Start/maintenance: children often titrated from ~10–20 mg/kg/day up to ~60 mg/kg/day; adults commonly 500–3000 mg/day in divided doses. Timing: bid. Purpose: first-line in many pediatric epilepsies. Mechanism: reduces synaptic release. Side effects: irritability, somnolence, dizziness. NCBI+1

2. Sodium valproate (broad-spectrum).
   Class: GABAergic/multiple. Children: often 20–30 mg/kg/day (special precautions in people who could conceive; strict pregnancy rules). Timing: bid–tid. Purpose: generalized seizures/mixtures. Mechanism: ↑GABA, Na⁺ channel effects. Side effects: weight gain, tremor, liver/pancreas toxicity; strict pregnancy restrictions per regulators/NICE. NHS England+1

3. Lamotrigine.
   Class: Na⁺ channel modulator. Pediatric titration: very slow (e.g., 0.3–0.6 mg/kg/day increasing over weeks); adult typical 100–400 mg/day depending on comeds. Purpose: focal/generalized; mood benefits. Mechanism: stabilizes membranes. Side effects: rash (rare SJS)—slow titration is critical. Drugs.com+1

4. Topiramate.
   Class: broad (Na⁺, GABA, AMPA). Dose: titrated by weight/response. Purpose: generalized and focal seizures. Side effects: appetite loss, cognitive slowing, kidney stones; pregnancy precautions. NICE

5. Clobazam.
   Class: benzodiazepine. Dose: weight-based; bedtime/bid. Purpose: add-on for refractory epilepsy. Side effects: sedation, tolerance, drooling. NICE

6. Clonazepam.
   Class: benzodiazepine. Use: myoclonic/atonic types; bridge therapy. Side effects: sedation, behavior changes. NICE

7. Oxcarbazepine.
   Class: Na⁺ channel. Use: focal seizures. Side effects: hyponatremia, rash. (Avoid in generalized epilepsies that worsen with Na⁺ agents.) NICE

8. Carbamazepine.
   Class: Na⁺ channel. Use: focal epilepsies. Side effects: hyponatremia, rash; may worsen some generalized seizure types. International League Against Epilepsy

9. Vigabatrin.
   Class: GABA-transaminase inhibitor. Use: infantile spasms/tuberous sclerosis; sometimes for refractory focal. Side effects: visual field defects (monitor eyes). NICE

10. Zonisamide.
    Class: Na⁺/T-type Ca²⁺. Use: add-on in focal/generalized. Side effects: appetite loss, kidney stones. NICE

11. Lacosamide.
    Class: slow Na⁺ channel inactivation. Use: focal refractory; sometimes generalized adjunct. Side effects: dizziness, PR-interval effects. NICE

12. Perampanel.
    Class: AMPA receptor antagonist. Use: adjunct for focal/generalized tonic-clonic; case reports suggest benefit in ROGDI-related KTS. Side effects: irritability, dizziness. BioMed Central

13. Cannabidiol (Epidiolex where available).
    Class: cannabinoid (non-psychoactive). Use: specific syndromes (e.g., LGS/Dravet), sometimes off-label if specialist recommends. Side effects: sleepiness, liver enzyme rise; drug interactions. NICE

14. Phenobarbital.
    Class: barbiturate. Use: neonatal seizures first-line; sometimes persistent epilepsy. Side effects: sedation, behavior effects. Wiley Online Library

15. Phenytoin/fosphenytoin.
    Class: Na⁺ channel. Use: status epilepticus or focal; careful monitoring. Side effects: arrhythmias (IV), gingival overgrowth. Wiley Online Library

16. Midazolam (buccal/intranasal) – rescue.
    Use: prolonged seizure/cluster per plan. Side effects: drowsiness; watch breathing. NICE

17. Diazepam (rectal/intranasal) – rescue.
    Use: home rescue for long seizures per plan. Side effects: sedation, respiratory depression if excessive. NICE

18. Valproate alternatives for people who must avoid it (e.g., women of child-bearing potential): levetiracetam or lamotrigine often preferred depending on seizure type and risks. NICE

19. Steroids (short courses) in specific epileptic encephalopathies (specialist-selected). Side effects: mood, glucose, infection risk. NCBI

20. Combination therapy (rational polytherapy) after two monotherapies fail—chosen by a specialist to minimize interactions and maximize seizure control. NCBI

---

Dietary molecular supplements

Evidence for supplements in epilepsy/KTS is limited. Use only with your clinician, especially alongside ketogenic therapy.

1. Vitamin D – supports bone/teeth; many ASMs lower D. Mechanism: calcium absorption, enamel/bone mineralization. BioMed Central

2. Calcium – partners with vitamin D for teeth/bone. Mechanism: mineral supply. BioMed Central

3. Phosphate (balanced intake) – proper mineralization. Mechanism: hydroxyapatite balance. BioMed Central

4. Magnesium – low levels can lower seizure threshold; correct deficiency only. Mechanism: NMDA modulation. NCBI

5. Omega-3 fatty acids – overall neuro health; mixed seizure evidence. Mechanism: membrane fluidity/anti-inflammatory. NCBI

6. Coenzyme Q10 – mitochondrial support (limited data). Mechanism: electron transport. NCBI

7. Carnitine (especially with valproate if advised) – counters rare carnitine depletion. Mechanism: fatty-acid transport. NCBI

8. B-complex (including folate) – general neural health; avoid interactions (e.g., high folate may affect ASM levels—specialist advice needed). NCBI

9. Probiotics – gut comfort, especially on ketogenic diet; seizure effect uncertain. Mechanism: microbiome balance. PMC

10. Electrolyte rehydration (sugar-free options) – helpful on ketogenic diets to avoid cramps/constipation; mechanism: fluid-electrolyte balance. PMC

---

Immunity booster / regenerative / stem-cell drugs

There are no proven immune-booster or stem-cell drugs that treat KTS or repair enamel/brain changes in this syndrome. Any “regenerative” therapy is experimental. What is appropriate is: (1) routine immunizations to prevent infections that can trigger seizures; (2) nutritional optimization; (3) dental reconstruction; (4) device therapy (VNS) in drug-resistant cases. Animal models of ROGDI deficiency exist to study mechanisms, but no clinical regenerative therapy is established. Nature

If a trial is proposed, ask for ethics approval details, phase, endpoints, and safety monitoring.

---

Surgeries or procedures

1. Vagus nerve stimulator (VNS) implantation – for drug-resistant epilepsy when resective surgery is unsuitable; aims to reduce seizure frequency/intensity (not a cure). NICE

2. Full-coverage crowns (stainless-steel for primary molars) under local/general anesthesia as needed – protect fragile enamel, stop pain, restore chewing. PMC

3. Composite/ceramic veneer rehabilitation (older children/adults) – esthetics and function with minimal tooth removal. ResearchGate

4. Extractions with space maintenance – when teeth are non-restorable or infected, to relieve pain and allow proper occlusion later. PMC

5. Orthognathic/orthodontic procedures (selected cases with open bite or jaw disharmony common in AI) – to improve bite and speech in late teens/adulthood. BioMed Central

---

Preventions

1. Genetic counseling & testing in at-risk families (autosomal recessive) to inform future pregnancies. NCBI

2. Early seizure treatment to reduce regression risk. NCBI

3. Seizure trigger control (sleep, illness, flashing lights for photosensitive types). NCBI

4. Medication adherence & regular reviews (at least annually per local care plans). Somerset Prescribing Formulary

5. Dental prevention: fluoride varnish, gentle brushing, low sugar/acid diet. AAPD

6. Scheduled dental check-ups (6–12 months) as teeth erupt. BioMed Central

7. Mouth protection if bruxism/sports. PMC

8. Infection prevention (vaccines, hand hygiene) – fevers can trigger seizures. NCBI

9. Rescue plan at school/home for prolonged seizures. NICE

10. Care coordination across neurology, dentistry, rehab, and school services. AAPD

---

When to see doctors urgently

• First seizure or any seizure >5 minutes (use rescue plan and call emergency services). NICE

• Seizure clusters, new seizure types, or injury during a seizure. NICE

• Breathing problems, bluish color, or not waking after a seizure. NICE

• Severe tooth pain, swelling, fever, or trouble eating/weight loss—possible dental infection. PMC

• Rapid loss of skills (speech, walking) or new persistent weakness. NCBI

---

What to eat and what to avoid

• If on a ketogenic or modified Atkins diet: follow the specialist plan exactly (weigh foods, track ketones as instructed). Focus on permitted high-fat proteins, allowed vegetables, and prescribed formulas; avoid sugars, juices, breads, cereals, starchy vegetables unless your team says otherwise. Epilepsy Foundation+1

• For enamel protection (any diet): choose soft, non-acidic foods during sensitivity; limit frequent sugars and acidic drinks (sodas, citrus sipping). Rinse with water after acidic foods; use fluoride. AAPD+1

• Everyday balance: adequate protein, calories, vitamin D, calcium for growth and teeth; consider dietitian support. BioMed Central

---

Frequently asked questions

1. Is there a cure?
   Not yet. Care focuses on seizure control, development, and dental rehabilitation. Research models of ROGDI deficiency are in progress. Nature

2. Is it always genetic?
   Yes—classical KTS is autosomal recessive (ROGDI). KTS-like conditions can be due to SLC13A5. Genetic testing clarifies which. PMC+1

3. Do all children lose skills?
   Severity varies. Early seizure control and therapies help protect function. NCBI

4. Which seizure medicine is “best”?
   No single best drug for everyone. Many start with levetiracetam, valproate (with strict pregnancy rules), or lamotrigine depending on seizure type and risks. Specialists tailor therapy. NICE

5. Can diet help?
   Yes. Ketogenic or related diets can reduce seizures in drug-resistant epilepsy when guided by an experienced team. NICE

6. Is VNS a cure?
   No. It often reduces seizure frequency/intensity but rarely stops seizures completely. NICE

7. Will the teeth always be yellow or fragile?
   Enamel does not “regrow,” but crowns/veneers and fluoride care protect teeth, reduce pain, and improve appearance. PMC

8. Can this be missed?
   Yes. Because enamel defects are common from other causes, the link to epilepsy can be overlooked without genetic testing. NCBI

9. Is pregnancy exposure to valproate a concern?
   Yes—strict safety measures apply. Alternatives are considered for people who could conceive. Follow national safety guidance. NICE

10. Are stem-cell therapies available?
    No approved regenerative or stem-cell treatments exist for KTS today. Nature

11. What about perampanel?
    Case experiences in ROGDI-related KTS suggest potential benefit in some individuals as add-on therapy. Decisions are individualized. BioMed Central

12. How often should we see the dentist?
    Every 6–12 months routinely (often 6 months during active eruption), sooner if pain or chipping occurs. BioMed Central

13. Can orthodontics be done?
    Yes, with special bonding approaches; some may need jaw surgery later for open bite. BioMed Central

14. Will seizures stop in adulthood?
    Course varies; many have long-term epilepsy. Ongoing follow-up is important. NCBI

15. What can families do today?
    Learn seizure first-aid, keep a rescue plan and diary, stick to meds/diet, schedule dental protection early, and connect with genetics and school supports. NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 14, 2025.

PDF Documents For This Disease Condition References